Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

Simpson, Kit N; Luo, Michelle P; Chumney, Elinor; Sun, Eugene; Brun, Scott; Ashraf, Talat

Simpson, Kit N; Luo, Michelle P; Chumney, Elinor; Sun, Eugene; Brun, Scott; Ashraf, Talat.

Affiliation

Simpson KN; Pharmacy and Clinical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA. SimpsonK@musc.edu

HIV Clin Trials ; 5(5): 294-304, 2004.

Article in En | MEDLINE | ID: mdl-15562370

Subject(s)

Antiretroviral Therapy, Highly Active/economics; HIV Infections/drug therapy; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cost-Benefit Analysis; Female; HIV Protease Inhibitors/administration & dosage; HIV Protease Inhibitors/economics; Humans; Illinois; Lopinavir; Male; Markov Chains; Middle Aged; Nelfinavir/administration & dosage; Nelfinavir/economics; Pyrimidinones/administration & dosage; Pyrimidinones/economics; Quality of Life; Ritonavir/administration & dosage; Ritonavir/economics; Viral Load

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Antiretroviral Therapy, Highly Active Type of study: Health_economic_evaluation Aspects: Patient_preference Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: HIV Clin Trials Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) / TERAPEUTICA Year: 2004 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links